RU2005105578A - Пэгилированный полипептид т1249 - Google Patents
Пэгилированный полипептид т1249 Download PDFInfo
- Publication number
- RU2005105578A RU2005105578A RU2005105578/04A RU2005105578A RU2005105578A RU 2005105578 A RU2005105578 A RU 2005105578A RU 2005105578/04 A RU2005105578/04 A RU 2005105578/04A RU 2005105578 A RU2005105578 A RU 2005105578A RU 2005105578 A RU2005105578 A RU 2005105578A
- Authority
- RU
- Russia
- Prior art keywords
- denotes
- compound
- pharmaceutical composition
- group
- nht1249
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (16)
1. Соединение формулы (I)
в которой R1 обозначает кэпгруппу;
m обозначает число от 1 до 17;
n обозначает число от 10 до 1000;
р обозначает число от 1 до 3; и
NHT1249 обозначает полипептид Т1249, ковалентно связанный через концевую α-аминогруппу.
2. Соединение по п.1, в котором R1 выбран из группы, включающей галоген, эпоксид, имид малеиновой кислоты, ортопиридилдисульфид, тозилат, изоцианат, гидразингидрат, циануровый галид, N-сукцинимидилоксигруппу, сульфо-N-сукцинимидилоксигруппу, 1-бензотриазолилоксигруппу, 1-имидазолилоксигруппу, пара-нитрофенилоксигруппу и
3. Соединение по п.1, в котором р обозначает 3.
4. Соединение по п.1, в котором р обозначает 3, R1 обозначает метоксигруппу, m обозначает 1 и n обозначает число от 100 до 750.
5. Соединение формулы
в которой n обозначает число от 10 до 1000; и
NHT1249 обозначает полипептид Т1249, ковалентно связанный через концевую α-аминогруппу.
6. Соединение по п.5, в котором n обозначает приблизительно число 450.
7. Фармацевтическая композиция, включающая, в смеси с фармацевтически приемлемым эксципиентом, соединение формулы
в которой R1 обозначает кэпгруппу;
m обозначает число от 1 до 17;
n обозначает число от 10 до 1000;
р обозначает число от 1 до 3; и
NHT1249 обозначает полипептид Т1249, ковалентно связанный через концевую α-аминогруппу.
8. Фармацевтическая композиция по п.7, в которой в предлагаемом соединении р обозначает 3, R1 обозначает метоксигруппу, m обозначает 1 и n обозначает число от 100 до 750.
9. Фармацевтическая композиция по п.7 в форме лиофилизированного порошка.
10. Фармацевтическая композиция по п.7 в форме раствора или суспензии для инъекций.
11. Применение фармацевтической композиции, включающей, в смеси с фармацевтически приемлемым эксципиентом, соединение формулы I, для приготовления лекарственного средства для ингибирования ВИЧ-инфекции
в которой R1 обозначает кэпгруппу;
m обозначает число от 1 до 17;
n обозначает число от 10 до 1000;
р обозначает число от 1 до 3; и
NHT1249 обозначает полипептид Т1249, ковалентно связанный через концевую α-аминогруппу.
12. Применение по п.11, в котором в предлагаемом соединении р обозначает 3, R1 обозначает метоксигруппу, m обозначает 1 и n обозначает число от 100 до 750.
13. Применение по п.11, в котором фармацевтическую композицию вводят инъекционно внутрибрюшинно, внутримышечно, подкожно, внутривенно или путем непрерывного вливания.
14. Применение по п.11, в котором фармацевтическую композицию вводят в количестве от приблизительно 50 до приблизительно 300 мг за введение.
15. Применение фармацевтической композиции, включающей, в смеси с фармацевтически приемлемым эксципиентом, соединение формулы III, для приготовления лекарственного средства для ингибирования ВИЧ-инфекции
в которой n обозначает число от 10 до 1000; и
NHT1249 обозначает полипептид Т1249, ковалентно связанный через концевую α-аминогруппу.
16. Применение по п.15, в котором фармацевтическую композицию вводят в количестве от приблизительно 300 до приблизительно 1500 мг в неделю в качестве однократной дозы.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39819002P | 2002-07-24 | 2002-07-24 | |
| US60/398,190 | 2002-07-24 | ||
| US43921303P | 2003-01-10 | 2003-01-10 | |
| US60/439,213 | 2003-01-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005105578A true RU2005105578A (ru) | 2005-10-27 |
| RU2294938C2 RU2294938C2 (ru) | 2007-03-10 |
Family
ID=31498587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005105578/04A RU2294938C2 (ru) | 2002-07-24 | 2003-07-16 | Пэгилированный полипептид т1249 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7084261B2 (ru) |
| EP (1) | EP1546193A1 (ru) |
| JP (1) | JP4381302B2 (ru) |
| KR (1) | KR100630176B1 (ru) |
| CN (1) | CN100352837C (ru) |
| AR (1) | AR040650A1 (ru) |
| AU (1) | AU2003250079B2 (ru) |
| BR (1) | BR0312841A (ru) |
| CA (1) | CA2492954C (ru) |
| HR (1) | HRP20050025A2 (ru) |
| IL (1) | IL166037A0 (ru) |
| MX (1) | MXPA05000798A (ru) |
| NO (1) | NO20050067L (ru) |
| NZ (1) | NZ537493A (ru) |
| PA (1) | PA8577801A1 (ru) |
| PE (1) | PE20040679A1 (ru) |
| PL (1) | PL375308A1 (ru) |
| RU (1) | RU2294938C2 (ru) |
| TW (1) | TW200427697A (ru) |
| UY (1) | UY27900A1 (ru) |
| WO (1) | WO2004013165A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7744897B2 (en) * | 2003-12-23 | 2010-06-29 | Dillon Susan B | Human immunodeficiency virus gp41 mimetibody polypeptides |
| WO2005080418A2 (en) * | 2004-02-23 | 2005-09-01 | Borean Pharma A/S | Multimerised hiv fusion inhibitors |
| MXPA06010505A (es) * | 2004-03-15 | 2006-12-19 | Nektar Therapeutics Al Corp | Composiciones y conjugados, basados en polimeros, de inhibidores de ingreso de vih. |
| CN100475270C (zh) * | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US5795569A (en) * | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
| CH690143A5 (de) * | 1995-01-27 | 2000-05-15 | Rieter Automotive Int Ag | Lambda/4-Schallabsorber. |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
| US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| US6281331B1 (en) * | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| US6469136B1 (en) * | 1999-07-07 | 2002-10-22 | Trimeris, Inc. | Methods and composition for peptide synthesis |
| RU2179980C2 (ru) * | 2000-03-20 | 2002-02-27 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Пептид-имитатор консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5 (варианты) |
-
2003
- 2003-07-16 RU RU2005105578/04A patent/RU2294938C2/ru not_active IP Right Cessation
- 2003-07-16 HR HR20050025A patent/HRP20050025A2/xx not_active Application Discontinuation
- 2003-07-16 MX MXPA05000798A patent/MXPA05000798A/es active IP Right Grant
- 2003-07-16 PL PL03375308A patent/PL375308A1/xx not_active Application Discontinuation
- 2003-07-16 NZ NZ537493A patent/NZ537493A/en unknown
- 2003-07-16 JP JP2004525220A patent/JP4381302B2/ja not_active Expired - Lifetime
- 2003-07-16 CA CA002492954A patent/CA2492954C/en not_active Expired - Fee Related
- 2003-07-16 KR KR1020057001145A patent/KR100630176B1/ko not_active Expired - Fee Related
- 2003-07-16 EP EP03766191A patent/EP1546193A1/en not_active Withdrawn
- 2003-07-16 IL IL16603703A patent/IL166037A0/xx unknown
- 2003-07-16 AU AU2003250079A patent/AU2003250079B2/en not_active Ceased
- 2003-07-16 CN CNB038176793A patent/CN100352837C/zh not_active Expired - Fee Related
- 2003-07-16 WO PCT/EP2003/007711 patent/WO2004013165A1/en not_active Ceased
- 2003-07-16 BR BR0312841-5A patent/BR0312841A/pt not_active IP Right Cessation
- 2003-07-18 TW TW092119718A patent/TW200427697A/zh unknown
- 2003-07-21 PE PE2003000723A patent/PE20040679A1/es not_active Application Discontinuation
- 2003-07-21 PA PA20038577801A patent/PA8577801A1/es unknown
- 2003-07-22 UY UY27900A patent/UY27900A1/es not_active Application Discontinuation
- 2003-07-22 US US10/625,103 patent/US7084261B2/en not_active Expired - Fee Related
- 2003-07-22 AR AR20030102620A patent/AR040650A1/es unknown
-
2005
- 2005-01-06 NO NO20050067A patent/NO20050067L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20040171542A1 (en) | 2004-09-02 |
| EP1546193A1 (en) | 2005-06-29 |
| PE20040679A1 (es) | 2004-10-06 |
| KR100630176B1 (ko) | 2006-10-02 |
| CA2492954A1 (en) | 2004-02-12 |
| PA8577801A1 (es) | 2004-05-26 |
| AU2003250079A1 (en) | 2004-02-23 |
| AU2003250079B2 (en) | 2006-07-27 |
| RU2294938C2 (ru) | 2007-03-10 |
| IL166037A0 (en) | 2006-01-15 |
| TW200427697A (en) | 2004-12-16 |
| CA2492954C (en) | 2009-12-22 |
| MXPA05000798A (es) | 2005-04-19 |
| PL375308A1 (en) | 2005-11-28 |
| NZ537493A (en) | 2007-05-31 |
| US7084261B2 (en) | 2006-08-01 |
| CN100352837C (zh) | 2007-12-05 |
| CN1671735A (zh) | 2005-09-21 |
| KR20050027255A (ko) | 2005-03-18 |
| WO2004013165A1 (en) | 2004-02-12 |
| JP4381302B2 (ja) | 2009-12-09 |
| HRP20050025A2 (en) | 2006-02-28 |
| UY27900A1 (es) | 2003-12-31 |
| BR0312841A (pt) | 2005-12-06 |
| AR040650A1 (es) | 2005-04-13 |
| NO20050067L (no) | 2005-04-22 |
| JP2006515272A (ja) | 2006-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005105577A (ru) | Пегилированный полипептид т20 | |
| WO2002008250A2 (en) | Ghrelin antagonists | |
| BRPI0310094B1 (pt) | composto de bis-(monoetanolamina) de ácido 3'-[(2z)-[1-(3,4-dimetilfenil)-1,5-diidro-3-metil-5-oxo-4h-pirazol-4-ilideno]hidrazino]-2'-hidróxi-[1,1'-bifenil]-3-carboxílico, composição farmacêutica e processos para preparar ditos composto e composição farmacêutica | |
| CA2361364A1 (en) | Dalda analogs and their use | |
| CZ167997A3 (en) | Physicologically active peg-ifn alpha conjugate, process of its preparation and pharmaceutical composition containing thereof | |
| JPH05955A (ja) | 水溶性高分子抗癌剤及び薬物担持用担体 | |
| EA020257B1 (ru) | НОВЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ | |
| RU2005105578A (ru) | Пэгилированный полипептид т1249 | |
| CN101306203A (zh) | 亲水性聚合物-黄杨木提取物的结合物及其药物组合物 | |
| US20090117077A1 (en) | Polyethylene glycol-interferon alpha conjugate | |
| RU2038080C1 (ru) | Лекарственное средство для парентерального введения | |
| EP1078635A3 (en) | Medicaments comprising sialic acid derivatives as active ingredients | |
| EP0241837B1 (en) | Stable injectable antiemetic compositions | |
| CA2296503A1 (en) | Medicinal compositions for treating immunodeficiency diseases | |
| TW592702B (en) | Pharmaceutical composition for treating diabetes | |
| FI57882B (fi) | Foerfarande foer framstaellning av en stabil tetracyklinloesning | |
| HK40097690A (en) | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| HU190513B (en) | Process for producing of new preparates consisting of hydrogenised ergot-alcaloids and hepharine with therapeutical effect | |
| WO1994016695A1 (en) | Pharmaceutical compositions containing cimetidine | |
| JP2001122780A (ja) | 抗悪性腫瘍薬 | |
| KR20040030709A (ko) | 티옥산테논을 포함하는 항종양성 제제 | |
| CA2487153A1 (en) | New formulation for the parenteral application of crobenetine | |
| WO2001000240A2 (en) | Antitumor compound | |
| KR20060095669A (ko) | 신규한 ５―플루오로우라실 좌제 조성물 | |
| JPH0461849B2 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20070717 |